The Lancet Oncology in conversation with

The Lancet Oncology in conversation with

By The Lancet GroupMedicineHealth & Fitness
Download on the App Store

The Lancet Oncology in conversation with episodes

  • Accelerating equitable cancer genomics and precision oncology with Raffaella Casolino and Mark Lawler

    In this special episode, Dr Cheryl Lai, Acting Deputy Editor at The Lancet Oncology, is joined by Dr Raffaella Casolino (University of Glasgow, UK; International Cancer Genome Consortium - Accelerating Research in Genomic Oncology) and Professor Mark Lawler (Queen's University Belfast, UK) to discuss the outcomes and implications of the latest Lancet Oncology Commission on cccelerating equitable cancer genomics and precision oncology in health care and research.

    Explore the Commission and related content:

    https://www.thelancet.com/commissions-do/accelerating-equitable-cancer-genomics

    Look at the infographic:

    https://www.thelancet.com/infographics-do/universal-access-precision-oncology

    Read the full Commission:

    https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00302-5

    16 min
  • Tumour-infiltrating lymphocytes in breast cancer with Professor Sherene Loi

    Professor Sherene Loi and the International Immuno-Oncology Biomarker Working Group on tumour-infiltrating lymphocytes as breast cancer biomarkers. Two Articles cover AI and digital pathology scoring methods and a Review examines integrating TILs into radiation oncology trials and clinical practice. The Articles and Review are published in the September 2026 issue of The Lancet Oncology.

    To read the publications discussed, see: 

    Tumour-infiltrating lymphocytes and breast radiotherapy: perspectives from the International Immuno-Oncology Biomarker Working Group:  https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00255-X

    Artificial intelligence-based tumour infiltrating lymphocyte quantification in patients with triple-negative breast cancer: an independent validation study  https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00339-6
     
    Manual, digital, and AI tumour-infiltrating lymphocyte scoring: a secondary analysis of the APHINITY randomised trial: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00247-0
    18 min
  • 5-year quality of life study of the SUPREMO trial examining chest wall radiotherapy in patients with intermediate-risk breast cancer with Professor Galina Velikova

    5-year quality of life (QOL) substudy of the SUPREMO trial examining the effects of chest wall radiotherapy versus no chest wall radiotherapy after mastectomy in patients with intermediate-risk breast cancer. The data will put patients in a better position to make an informed treatment decision considering long-term QOL effects for intermediate-risk early breast cancer.

    Click here to read the full article:

    https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00122-1/fulltext

    12 min
  • Hans Merks on European guidelines for imaging of primary paediatric and adult osteosarcoma and Ewing sarcoma

    Imaging is central to osteosarcoma and Ewing sarcoma diagnosis and treatment, yet no international consensus defines optimal modalities or schedules to date. Hans presents harmonised European recommendations for the imaging of bone sarcomas, fulfilling the requirement for a methodical, systematic, and uniform approach to the diagnosis, treatment response assessment and post-therapy surveillance of osteosarcoma and Ewing sarcoma.

    Click here to read the full article: 

    https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00141-5/fulltext

    13 min
  • Hedvig Hricak and Zachary Ward on Cancer workforce—a global crisis: a Lancet Oncology Commission

    Jamie Prowse, Senior Editor at The Lancet Oncology, is joined by Dr Hedvig Hricak (Memorial Sloan Kettering Cancer Center, New York, NY, USA) and Dr Zachary Ward (Harvard TH Chan School of Public Health, Boston, MA, USA) to discuss Cancer workforce—a global crisis: a Lancet Oncology Commission.

    To discover more about the commission click here: www.thelancet.com/commissions-do/cancer-workforce.

    To read the full commission click here: https://doi.org/10.1016/S1470-2045(26)00065-3

    24 min
  • Fred Saad on quality of life in patients with metastatic hormone-sensitive prostate cancer

    Cheryl Lai, Acting Deputy Editor of The Lancet Oncology, is joined by Professor Fred Saad (Department of Surgery/Urology, University of Montreal, Montreal, QC, Canada) to discuss pain and health-related quality-of-life outcomes from the randomised phase 3 ARANOTE trial of darolutamide in metastatic hormone-sensitive prostate cancer. Hear about the findings from the study, the importance of quality of life for patients with metastatic prostate cancer, and how clinical research in metastatic hormone-sensitive prostate cancer might look in the next 5 years.

    Read the full article: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00014-8/fulltext

    14 min
  • James Nagarajah on [177Lu]-PSMA-617-PSMA-617 in oligometastatic hormone sensitive prostate cancer (BULLSEYE): an open-label, randomised, phase 2 study

    Cheryl Reeves, Senior Editor at The Lancet Oncology, is joined by Professor James Nagarajah to discuss his open-label, randomised, phase 2 study [177Lu]-PSMA-617-PSMA-617 in oligometastatic hormone sensitive prostate cancer (BULLSEYE).

    Click here to read the full article: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00762-4/fulltext

    Tell us what you thought about this episode

    Medical imaging and theranostics are revolutionising how we diagnose, treat, and understand disease. To meet this moment, The Lancet group is happy to announce the launch of, The Lancet Medical Imaging and Theranostics. 

    You can visit https://www.thelancet.com/medical-imaging-theranostics to learn more.

    Continue this conversation on social!

    Follow us today at...
    https://thelancet.bsky.social/
    https://instagram.com/thelancetgroup
    https://facebook.com/thelancetmedicaljournal
    https://linkedIn.com/company/the-lancet
    https://youtube.com/thelancettv

    11 min
  • Ali Landman on the European Congress of Radiology 2026

    Join us for this special episode where Deputy Editor Cheryl Lai speaks with Ali Landman, Editor-in-Chief of The Lancet Medical Imaging & Theranostics, about the scope and vision of the new journal and Ali's highlights in oncological imaging from the European Congress of Radiology in Vienna, March 4-8, 2026.


    To learn more:
    European Congress of Radiology: https://www.myesr.org/congress/

    The Lancet Medical Imaging & Theranostics: https://www.thelancet.com/medical-imaging-theranostics

    For presubmission enquiries and other questions email [email protected]

    To submit your manuscript: https://www2.cloud.editorialmanager.com/thelancetimaging/default2.aspx


    Join The Lancet Medical Imaging & Theranostics’ editorial team for a Lancet Webinar dedicated to helping you publish with The Lancet Medical Imaging & Theranostics https://hubs.li/Q042sbn40

    Find us on LinkedIn and Bluesky @lancetimaging.bsky.social

    Tell us what you thought about this episode

    Medical imaging and theranostics are revolutionising how we diagnose, treat, and understand disease. To meet this moment, The Lancet group is happy to announce the launch of, The Lancet Medical Imaging and Theranostics. 

    You can visit https://www.thelancet.com/medical-imaging-theranostics to learn more.

    Continue this conversation on social!

    Follow us today at...
    https://thelancet.bsky.social/
    https://instagram.com/thelancetgroup
    https://facebook.com/thelancetmedicaljournal
    https://linkedIn.com/company/the-lancet
    https://youtube.com/thelancettv

    15 min
  • Kayleigh Bhangdia on breast cancer GBD study 2023

    Kayleigh Bhangdia discusses the latest GBD breast cancer study data, telling the audience about epidemiological trends, disease burden, and risk factors associated with breast cancer globally, regionally, and nationally for 204 countries from 1990 to 2023. Kayleigh sheds light on disparities in breast cancer burden across the globe and forecasts to 2050, and highlights the the most critical areas that future GBD studies should focus on to improve the accuracy, relevance, and impact of breast cancer estimates worldwide.

    https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00730-2/fulltext

    Tell us what you thought about this episode

    Medical imaging and theranostics are revolutionising how we diagnose, treat, and understand disease. To meet this moment, The Lancet group is happy to announce the launch of, The Lancet Medical Imaging and Theranostics. 

    You can visit https://www.thelancet.com/medical-imaging-theranostics to learn more.

    Continue this conversation on social!

    Follow us today at...
    https://thelancet.bsky.social/
    https://instagram.com/thelancetgroup
    https://facebook.com/thelancetmedicaljournal
    https://linkedIn.com/company/the-lancet
    https://youtube.com/thelancettv

    19 min
  • Dylan Graetz and Erica Kaye on qualitative research in oncology

    Jamie Prowse, Senior Editor at The Lancet Oncology, is joined by Dr Dylan Graetz (Department of Oncology and Department of Global Pediatric Medicine, St Jude Children’s Research Hospital) and Dr Erica Kaye (Department of Oncology, St Jude Children’s Research Hospital) to discuss qualitative in oncology.


    Read the full Reviews:

    https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00669-2 for The Power of Words: Evaluating the Role of Qualitative Methods in Cancer Research
    and
    https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00670-9 for Expert Recommendations for the Conduct and Appraisal of Qualitative Research in Oncology

    and the reviews in  Lancet Haematology 2026  https://doi.org/10.1016/S2352-3026(25)00321-7

    and eClinicalMedicine https://doi.org/10.1016/j.eclinm.2025.103736

    Tell us what you thought about this episode

    Medical imaging and theranostics are revolutionising how we diagnose, treat, and understand disease. To meet this moment, The Lancet group is happy to announce the launch of, The Lancet Medical Imaging and Theranostics. 

    You can visit https://www.thelancet.com/medical-imaging-theranostics to learn more.

    Continue this conversation on social!

    Follow us today at...
    https://thelancet.bsky.social/
    https://instagram.com/thelancetgroup
    https://facebook.com/thelancetmedicaljournal
    https://linkedIn.com/company/the-lancet
    https://youtube.com/thelancettv

    43 min

About The Lancet Oncology in conversation with

From the publisher's feed

Editors at The Lancet Oncology, in conversation with the journal’s authors, explore their latest research and its impact on people’s health, healthcare, and health policy. A monthly audio companion to…

More shows like The Lancet Oncology in conversation with

JAMA Editors' Summary by JAMA Network

JAMA Editors' Summary

136 Listeners

Annals of Internal Medicine Podcast by American College of Physicians

Annals of Internal Medicine Podcast

137 Listeners

NEJM This Week by NEJM Group

NEJM This Week

320 Listeners

JAMA Clinical Reviews by JAMA Network

JAMA Clinical Reviews

498 Listeners

Journal of Clinical Oncology (JCO) Podcast by American Society of Clinical Oncology (ASCO)

Journal of Clinical Oncology (JCO) Podcast

40 Listeners

Medicine and Science from The BMJ by The BMJ

Medicine and Science from The BMJ

36 Listeners

Nature Podcast by Springer Nature Limited

Nature Podcast

769 Listeners

THE ADAM BUXTON PODCAST by ADAM BUXTON

THE ADAM BUXTON PODCAST

1,166 Listeners

Science Magazine Podcast by Science Magazine

Science Magazine Podcast

821 Listeners

The Peter Attia Drive by Peter Attia, MD

The Peter Attia Drive

7,977 Listeners

Blood Podcast by American Society of Hematology

Blood Podcast

51 Listeners

The Lancet Voice by The Lancet Group

The Lancet Voice

21 Listeners

The Lancet Child & Adolescent Health in conversation with by The Lancet Group

The Lancet Child & Adolescent Health in conversation with

0 Listeners

The Lancet Digital Health in conversation with by The Lancet Group

The Lancet Digital Health in conversation with

0 Listeners

The Lancet Global Health in conversation with by The Lancet Group

The Lancet Global Health in conversation with

2 Listeners

The Lancet Psychiatry in conversation with by The Lancet Group

The Lancet Psychiatry in conversation with

0 Listeners

The Lancet Respiratory Medicine in conversation with by The Lancet Group

The Lancet Respiratory Medicine in conversation with

1 Listeners

The Lancet in conversation with by The Lancet Group

The Lancet in conversation with

0 Listeners

The Lancet Haematology in conversation with by The Lancet Group

The Lancet Haematology in conversation with

0 Listeners

The Lancet Gastroenterology & Hepatology in conversation with by The Lancet Group

The Lancet Gastroenterology & Hepatology in conversation with

0 Listeners

The Lancet Diabetes & Endocrinology in conversation with by The Lancet Group

The Lancet Diabetes & Endocrinology in conversation with

1 Listeners

The Lancet Infectious Diseases in conversation with by The Lancet Group

The Lancet Infectious Diseases in conversation with

0 Listeners

The Lancet Public Health in conversation with by The Lancet Group

The Lancet Public Health in conversation with

1 Listeners

The Lancet Microbe in conversation with by The Lancet Group

The Lancet Microbe in conversation with

0 Listeners

eBioMedicine in conversation with by The Lancet Group

eBioMedicine in conversation with

0 Listeners

In conversation with... by The Lancet Neurology

In conversation with...

0 Listeners

The Lancet Rheumatology in conversation with by The Lancet Group

The Lancet Rheumatology in conversation with

0 Listeners

The Lancet Regional Health Western Pacific in conversation with by The Lancet Group

The Lancet Regional Health Western Pacific in conversation with

0 Listeners

The Lancet Primary Care in conversation with by The Lancet Group

The Lancet Primary Care in conversation with

0 Listeners

The Lancet Regional Health Americas in conversation with by The Lancet Group

The Lancet Regional Health Americas in conversation with

0 Listeners